Analyst report boosted United Therapeutics' price target from $525 to $625.
1 report, 1 independent
Updated Jun 6
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analyst report boosted United Therapeutics' price target from $525 to $625.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
United Therapeutics
biotech company based in Silver Spring, Maryland, United States
-
Cantor Fitzgerald
American financial services company
Related events
- Analyst provides a high price target for Viking Therapeutics stock.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Cantor Fitzgerald lifted its price target for ARS Pharmaceuticals, Inc. on June 1, 2026.
- TD Cowen, Morgan Stanley, Cantor Fitzgerald, Benchmark, and other firms adjusted price targets for Snowflake Inc. on August 31, 2026.